Cynosure Inc - Quarterly Report (10-Q)

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Form 10-Q

(Mark one)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2008

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 000-51623

Cynosure, Inc.

(Exact name of registrant as specified in its charter)

Delaware

04-3125110

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

5 Carlisle Road

Westford, MA

01886

(Address of principal executive offices)

(Zip code)

(978) 256-4200

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ¨ Yes x No

The number of shares outstanding of each of the registrant’s classes of common stock, as of August 4, 2008:


Class		Number of Shares
Class A Common Stock, $0.001 par value		9,690,574
Class B Common Stock, $0.001 par value		2,975,297

Cynosure, Inc.

Table of Contents


		Page No.
PART I	Financial Information
Item 1.	Financial Statements (Unaudited)
	Consolidated Balance Sheets as of June 30, 2008 and December 31, 2007	1
	Consolidated Statements of Income for the Three and Six Month Periods Ended June 30, 2008 and 2007	2
	Consolidated Statements of Cash Flows for the Six Month Periods Ended June 30, 2008 and 2007	3
	Notes to Consolidated Financial Statements	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20
Item 4.	Controls and Procedures	21

PART II	Other Information	22
Item 1.	Legal Proceedings	22
Item 1A.	Risk Factors	23
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 4.	Submission of Matters to a Vote of Security Holders	23
Item 6.	Exhibits	24
SIGNATURES		25
EXHIBIT INDEX		26
EX-31.1 Section 302 Certification of Principal Executive Officer
EX-31.2 Section 302 Certification of Principal Financial Officer
EX-32.1 Section 906 Certification of Chief Executive Officer
EX-32.2 Section 906 Certification of Chief Financial Officer

Cynosure, Inc.

Consolidated Balance Sheets

(Unaudited, in thousands)


	June 30, 2008			December 31, 2007
Assets
Current assets:
Cash and cash equivalents (Note 4)	$	50,468		$	39,011
Marketable securities (Notes 4 and 5)		19,492			47,086
Accounts receivable, net		36,461			24,124
Amounts due from related party (Note 11)		20			8
Inventories		24,777			22,442
Prepaid expenses and other current assets		3,640			4,425
Deferred income taxes		4,651			4,161

Total current assets		139,509			141,257

Property and equipment, net		8,749			7,146
Long-term investments (Notes 4 and 5)		21,506			—
Other assets		1,997			1,441

Total assets	$	171,761		$	149,844


Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	6,811		$	2,810
Amounts due to related party (Note 11)		3,163			2,311
Accrued expenses		19,209			17,980
Deferred revenue		5,931			3,939
Capital lease obligation		450			485

Total current liabilities		35,564			27,525

Capital lease obligation, net of current portion		593			794
Deferred revenue, net of current portion		484			421
Other noncurrent liability		490			226
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.001 par value
Authorized—5,000 shares
Issued — none		—			—
Class A and Class B common stock, $0.001 par value
Authorized — 70,000 shares
Issued — 12,566 and 12,448 shares as of June 30, 2008 and December 31, 2007, respectively		13			12
Additional paid-in capital		106,102			101,298
Retained earnings		29,861			20,332
Accumulated other comprehensive loss		(1,059	)		(477	)
Treasury stock, 36 shares, at cost		(287	)		(287	)

Total stockholders’ equity		134,630			120,878

Total liabilities and stockholders’ equity	$	171,761		$	149,844

The accompanying notes are an integral part of these consolidated financial statements.

Cynosure, Inc.

Consolidated Statements of Income

(Unaudited, in thousands, except per share data)


	Three Months Ended June 30,					Six Months Ended June 30,
	2008			2007		2008		2007
Revenues	$	39,195		$	30,132	$	75,958	$	56,209
Cost of revenues		12,878			11,068		25,249		20,990

Gross profit		26,317			19,064		50,709		35,219

Operating expenses:
Sales and marketing		14,085			9,875		27,279		19,137
Research and development		1,801			1,767		3,614		3,490
General and administrative		3,638			2,933		7,125		5,228

Total operating expenses		19,524			14,575		38,018		27,855

Income from operations		6,793			4,489		12,691		7,364

Interest income, net		627			596		1,428		1,101
Other (expense) income, net		(120	)		28		434		84

Income before provision for income taxes		7,300			5,113		14,553		8,549

Provision for income taxes		2,640			2,402		5,024		3,720

Net income	$	4,660		$	2,711	$	9,529	$	4,829

Basic net income per share	$	0.37		$	0.23	$	0.76	$	0.41

Diluted net income per share	$	0.36		$	0.21	$	0.75	$	0.39

Basic weighted-average common shares outstanding		12,513			11,964		12,492		11,654

Diluted weighted-average common shares outstanding		12,797			12,686		12,782		12,530

The accompanying notes are an integral part of these consolidated financial statements.

Cynosure, Inc.

Consolidated Statements of Cash Flows

(Unaudited, in thousands)


	Six Months Ended June 30,
	2008			2007
Operating activities:
Net income	$	9,529		$	4,829
Reconciliation of net income to net cash provided by operating activities:
Depreciation and amortization		1,860			1,327
Stock-based compensation expense		3,568			2,847
Accretion of discounts on marketable securities		208			127
Deferred income taxes		(26	)		8
Changes in operating assets and liabilities:
Accounts receivable		(11,672	)		(1,853	)
Due from related party		(14	)		325
Inventories		(1,807	)		(4,455	)
Net book value of demonstration inventory sold		207			150
Prepaid expenses and other current assets		(153	)		1,557
Accounts payable		3,948			(895	)
Due to related party		852			1,326
Accrued expenses		951			3,417
Deferred revenue		1,995			1,650
Other noncurrent liability		264			35

Net cash provided by operating activities		9,710			10,395

Investing activities:
Purchases of property and equipment		(3,612	)		(1,990	)
Proceeds from the sales and maturities of marketable securities		28,720			32,203
Purchases of marketable securities		(24,161	)		(37,150	)
Decrease in other noncurrent assets		11			4

Net cash provided by (used in) investing activities		958			(6,933	)

Financing activities:
Payment on short term loan		—			(168	)
Proceeds from exercise of stock options		661			4,563
Tax benefits related to stock options		969			1,864
Payments on capital lease obligation		(235	)		(208	)

Net cash provided by financing activities		1,395			6,051

Effect of exchange rate changes on cash and cash equivalents		(606	)		(91	)

Net increase in cash and cash equivalents		11,457			9,422
Cash and cash equivalents, beginning of the period		39,011			13,690

Cash and cash equivalents, end of the period	$	50,468		$	23,112

Supplemental cash flow information
Cash paid for interest	$	67		$	80

Cash paid for taxes	$	3,797		$	—

Supplemental noncash investing and financing activities
Net unrealized loss on marketable securities, net of $466 deferred income tax benefit, for the six months ended June 30, 2008	$	854		$	—

Assets acquired under capital lease	$	—		$	66

The accompanying notes are an integral part of these consolidated financial statements.

Cynosure, Inc.

Notes to Consolidated Financial Statements

Note 1 — Interim Consolidated Financial Statements

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. It is recommended that these financial statements be read in conjunction with the consolidated financial statements and related notes that appear in the Annual Report on Form 10-K of Cynosure, Inc. (Cynosure) for the year ended December 31, 2007. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position, results of operations, and cash flows as of the dates and for the periods presented have been included. The results of operations for the six months ended June 30, 2008 may not be indicative of the results that may be expected for the year ended December 31, 2008, or any other period.

Note 2 — Stock-Based Compensation

Cynosure recorded stock-based compensation expense of $1.9 million and $1.5 million and related tax benefits of $603,000 and $472,000 for the three months ended June 30, 2008 and 2007, respectively. Cynosure recorded stock-based compensation expense of $3.6 million and $2.8 million and related tax benefits of $1.1 million and $880,000 for the six months ended June 30, 2008 and 2007, respectively. Cynosure capitalized $69,000 and $39,000 of stock-based compensation expense as part of inventory as of June 30, 2008 and 2007, respectively.

Total stock-based compensation expense was recorded to cost of revenues and operating expenses based upon the functional responsibilities of the individual holding the respective options, as follows:


	Six Months Ended June 30,
	2008		2007
	(In thousands)
Cost of revenues	$	266	$	169
Sales and marketing		1,501		715
Research and development		530		981
General and administrative		1,271		982

Total stock-based compensation expense	$	3,568	$	2,847

Cash received from option exercises was $661,000 and $4,563,000 during the six months ended June 30, 2008 and 2007, respectively. Cynosure recognized $969,000 and $1,864,000 in actual tax benefits during the six months ended June 30, 2008 and 2007, respectively. Actual tax benefits are primarily the result of disqualifying dispositions of incentive stock options exercised which result in a reduction of income taxes payable.

Cynosure granted 251,750 and 295,750 stock options during the six months ended June 30, 2008 and 2007, respectively. Cynosure has elected to use the Black-Scholes model to determine the weighted average fair value of options, rather than a binomial model. The weighted-average fair value of the options granted during the six months ended June 30, 2008 and 2007 was $13.99 and $14.93 using the following assumptions:


	Six Months Ended June 30,
	2008		2007
Risk-free interest rate	2.19% - 2.46	%	4.64% - 4.77	%
Expected dividend yield	—		—
Expected lives	5.8 years		5.8 years
Expected volatility	64%		70%
Estimated forfeiture rate	5%		1%

Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. Due to the limited trading history of Cynosure’s common stock, which has been publicly traded since December 2005, Cynosure’s estimated expected stock price volatility is based on a weighted average of its own historical volatility and of the average volatilities of other guideline companies in the same industry. Cynosure believes this is more reflective and a better indicator of the expected future volatility, than using an average of a comparable market index or of a single comparable company in the same industry. Cynosure’s expected term of options granted in the six months ended June 30, 2008 and 2007 was derived from the short-cut method described in SEC’s Staff Accounting Bulletin (SAB) No. 107. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield of zero is based on the fact that Cynosure has never paid cash dividends and has no present intention to pay cash dividends.

During the year ended December 31, 2007, Cynosure applied an estimated annual forfeiture rate of 1% in determining the expense recorded in the consolidated statements of income. Upon review of its actual rate of forfeitures since the adoption of SFAS 123(R) and in consideration of management’s expectations for future forfeitures, Cynosure changed its estimated annual forfeiture rate in the fourth quarter of 2007 from 1% to 5%. This change in estimate was applied retrospectively and Cynosure recorded a cumulative catch-up adjustment during the quarter ended December 31, 2007.

Note 3 — Inventories

Cynosure states all inventories at the lower of cost or market, determined on a first-in, first-out method. Inventory includes material, labor and overhead and consists of the following:


	June 30, 2008		December 31, 2007
	(in thousands)
Raw materials	$	2,381	$	1,467
Work in process		862		395
Finished goods		21,534		20,580

	$	24,777	$	22,442

Note 4 — Fair Value

Effective January 1, 2008, Cynosure adopted FASB Statement No. 157, Fair Value Measurements (SFAS 157). SFAS 157 defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under SFAS 157 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under SFAS 157 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:

•

Level 1 – Quoted prices in active markets for identical assets or liabilities.

•

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable markets data for substantially the full term of the assets or liabilities.

•

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

In accordance with SFAS 157, the following table represents Cynosure’s fair value hierarchy for its financial assets (cash equivalents, marketable securities and long-term investments) measured at fair value as of June 30, 2008 (in thousands):


	Level 1		Level 2		Level 3		Total
Money market funds	$	34,181	$	—	$	—	$	34,181
State and municipal bonds		—		15,738		—		15,738
Corporate bonds		—		788		—		788
Equity securities		16		—		—		16
Auction rate securities		2,950		—		21,506		24,456

Total	$	37,147	$	16,526	$	21,506	$	75,179

Level 3 assets consist of tax exempt certificates with an auction reset feature (auction rate securities) whose underlying assets are generally student loans, which are substantially backed by the federal government. In February 2008, auctions began to fail for these securities and each auction since then has failed, with one exception. Based on the overall failure rate of these auctions, the frequency of the failures, and the underlying maturities of the securities, a portion of which are greater than 30 years, Cynosure has classified $21.5 million of its auction rate securities portfolio as long-term assets on its consolidated balance sheet. The remaining $2.95 million of auction rate securities was classified as marketable securities in current assets at full par value, without any discount applied to its value, as an announcement was made in June 2008 that the underlying student loan obligation was to be called at full par value. On July 1, 2008, this auction rate security was successfully called at full par value and Cynosure received cash proceeds of $2.95 million.

Cynosure’s investments in auction rate securities were valued at fair value as of June 30, 2008. Given the current failures in the auction markets to provide quoted market prices of the securities, as well as the lack of any correlation of these instruments to other observable market data, Cynosure valued these securities using a discounted cash flow methodology with the most significant input categorized as Level 3. Significant inputs that went into the model were the credit quality of the issuer, the percentage and types of guarantees (such as Federal Family Education Loan Program – FFELP), the probability of the auction succeeding or the security being called, the estimated period to liquidation, and an illiquidity discount factor. Based on these inputs, discounts from par ranged from 3% to 12% with a weighted average discount across the portfolio of 4%. Changes in the assumptions of Cynosure’s model based on dynamic market conditions could have a significant impact on the valuation of these securities, which may lead Cynosure to record an impairment charge for these securities in the future.

On July 9, 2008, Cynosure received cash proceeds of approximately $1.2 million related to another investment in auction rate securities, which was successfully called at full par value. As of June 30, 2008, this investment was included in long-term assets and valued accordingly, as the announcement of the settlement was not made until July.

The following table provides a summary of changes in fair value of Cynosure’s Level 3 financial assets for the six months ended June 30, 2008 (in thousands):


	Auction Rate Securities
Balance at December 31, 2007	$	29,300
Unrealized loss included in other accumulated comprehensive income		(1,319	)
Transfer to Level 1 financial assets		(2,950	)
Net settlements		(3,525	)

Balance at June 30, 2008	$	21,506

Note 5 — Marketable Securities and Long-Term Investments

Cynosure accounts for investments as available-for-sale securities in accordance with SFAS No. 115, Accounting for Certain Investments in Debt and Equity Securities (SFAS 115). Under SFAS 115, securities purchased to be held for indefinite periods of time and not intended at the time of purchase to be held until maturity are classified as available-for-sale securities with any unrealized gains and losses reported as a separate component of accumulated other comprehensive loss. Cynosure continually evaluates whether any marketable investments have been impaired and, if so, whether such impairment is temporary or other than temporary.

The following table summarizes Cynosure’s investments as of June 30, 2008, all of which are classified as available-for-sale (in thousands):


	Market Value		Amortized Cost		Unrealized Gains		Unrealized Losses
Short-term investments:
State and municipal bonds	$	15,738	$	15,705	$	33	$	—
Corporate bonds		788		793		—		(5	)
Equity securities		16		8		8		—
Auction rate securities		2,950		2,950		—		—

Total short-term investments	$	19,492	$	19,456	$	41	$	(5	)
Long-term investments:
Auction rate securities	$	21,506	$	22,825	$	—	$	(1,319	)

Total short and long-term investments	$	40,998	$	42,281	$	41	$	(1,324	)

As of June 30, 2008, Cynosure’s debt securities mature as follows (in thousands):


	Total		Maturities
	Total		Less Than One Year		One to Five Years		More than five years
State and municipal bonds	$	15,738	$	12,562	$	3,176	$	—
Corporate bonds		788		—		788		—
Auction rate securities		24,456		2,950		—		21,506

Total debt securities	$	40,982	$	15,512	$	3,964	$	21,506

Approximately $4.15 million in cash proceeds was received subsequent to June 30, 2008 related to two settlements of Cynosure’s investments in auction rate securities. See Note 4.

The unrealized losses in auction rate securities were due principally to illiquidity in the marketplace (see Note 4 for further discussion of fair value). Cynosure does not consider these investments to be other-than-temporarily impaired at June 30, 2008. Cynosure has the ability and the intent to hold these investments until a successful auction occurs and the auction rate securities are liquidated at par value. As previously discussed above, Cynosure has also experienced the successful call of the underlying student loan obligations for certain auction rate securities at full par value. If in the future it is determined that any decline in values of the auction rate securities is other-than-temporary, Cynosure would have to recognize the loss in the statement of income, which could have a material impact on the operating results in the period during which it is recognized.

Note 6 — Warranty Costs

Cynosure typically provides a one-year parts and labor warranty on end-user sales of laser systems. Distributor sales generally include a warranty on parts only. Estimated future costs for initial product warranties are provided at the time of revenue recognition.

The following table provides the detail of the change in Cynosure’s product warranty accrual during the six months ended June 30, 2008, which is a component of accrued expenses in the consolidated balance sheets:


	June 30, 2008
	(in thousands)
Warranty accrual, beginning of period	$	3,094
Charged to costs and expenses relating to new sales		1,894
Costs incurred		(1,720	)

Warranty accrual, end of period	$	3,268

Note 7 — Segment Information

In accordance with SFAS No. 131, Disclosures about Segments of an Enterprise and Related Information (SFAS 131), operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. Cynosure’s chief decision-maker, as defined under SFAS 131, is a combination of the Chief Executive Officer and the Chief Financial Officer. Cynosure views its operations and manages its business as one segment, aesthetic treatment products and services.

The following table represents total revenue by geographic destination:


	Three Months Ended June 30,				Six Months Ended June 30,
	2008		2007		2008		2007
	(in thousands)
United States	$	24,291	$	16,197	$	47,831	$	30,276
Europe		7,763		7,088		14,787		14,087
Asia / Pacific		3,729		3,662		7,507		6,214
Other		3,412		3,185		5,833		5,632

Total	$	39,195	$	30,132	$	75,958	$	56,209

Net assets by geographic area are as follows:


	June 30, 2008			December 31, 2007
	(in thousands)
United States	$	129,686		$	118,074
Europe		8,414			6,116
Asia / Pacific		704			837
Eliminations		(4,174	)		(4,149	)

Total	$	134,630		$	120,878

Long-lived assets by geographic area are as follows:


	June 30, 2008		December 31, 2007
	(in thousands)
United States	$	9,304	$	7,829
Europe		1,225		589
Asia / Pacific		217		169

Total	$	10,746	$	8,587

No individual country within Europe or Asia/Pacific represented greater than 10% of total revenue, net assets or long-lived assets for any period presented.

Note 8 — Net Income Per Common Share

Basic net income per share was determined by dividing net income by the weighted average common shares outstanding during the period. Diluted net income per share was determined by dividing net income by diluted weighted average shares outstanding. Diluted weighted average shares reflect the dilutive effect, if any, of common stock options based on the treasury stock method.

A reconciliation of basic and diluted shares is as follows:


	Three Months Ended June 30,		Six Months Ended June 30,
	2008	2007	2008	2007
	(in thousands)
Basic weighted-average number of shares outstanding	12,513	11,964	12,492	11,654
Potential common shares pursuant to stock options	284	722	290	876

Diluted weighted-average number of shares outstanding	12,797	12,686	12,782	12,530

During the six months ended June 30, 2008 and 2007 approximately 491,000 and 273,000 shares, respectively, were excluded from the calculation of diluted weighted average common shares outstanding as the effect would have been anti-dilutive.

Note 9 — Comprehensive Income (Loss)

Comprehensive income (loss) is the change in equity of a company during a period from transactions and other events and circumstances, excluding transactions resulting from investments by owners and distributions to owners.

The components of accumulated other comprehensive loss as of June 30, 2008 and December 31, 2007 are as follows:


	June 30, 2008			December 31, 2007
	(in thousands)
Unrealized (loss) gain on marketable securities, net of taxes	$	(828	)	$	26
Cumulative translation adjustment		(231	)		(503	)

Total accumulated other comprehensive loss	$	(1,059	)	$	(477	)

The components of total comprehensive income for the three and six month periods ended June 30, 2008 and 2007 are as follows:


	Three Months Ended June 30,						Six Months Ended June 30,
	2008			2007			2008			2007
	(in thousands)
Reported net income	$	4,660		$	2,711		$	9,529		$	4,829
Cumulative translation adjustment		(75	)		50			272			45
Unrealized loss on marketable securities		(169	)		(53	)		(854	)		(51	)

Total comprehensive income	$	4,416		$	2,708		$	8,947		$	4,823

Note 10 — Litigation

In May 2005, Dr. Ari Weitzner, individually and as putative representative of a purported class, filed a complaint against Cynosure under the federal Telephone Consumer Protection Act (TCPA) in Massachusetts Superior Court in Middlesex County seeking monetary damages, injunctive relief, costs and attorneys fees. The complaint alleges that Cynosure violated the TCPA by sending unsolicited advertisements by facsimile to the plaintiff and other recipients without the prior express invitation or permission of the recipients. Under the TCPA, recipients of unsolicited facsimile advertisements are entitled to damages of up to $500 per facsimile for inadvertent violations and up to $1,500 per facsimile for knowing or willful violations. Based on discovery in this matter, the plaintiff alleges that approximately three million facsimiles were sent on Cynosure’s behalf by a third party to approximately 100,000 individuals. On February 6, 2008, several months after the close of discovery, the plaintiff served a motion for class certification, which Cynosure vigorously opposed on numerous factual and legal grounds, including that a nationwide class action may not be maintained in a Massachusetts state court by Dr. Weitzner, a New York resident; individual issues predominate over common issues; a class action is not superior to other methods of resolving TCPA claims; and Dr. Weitzner is an inadequate class representative. The Company also believes it has many merits defenses, including that the faxes in question do not constitute “advertising” within the meaning of the TCPA and many recipients had an established business relationship with the Company and are thereby deemed to have consented to the receipt of facsimile communications. The court held a hearing on the plaintiff’s class certification motion on June 17, 2008. On July 16, 2008, Cynosure commenced a declaratory judgment action in the United States District Court for the District of Massachusetts requesting a declaration that Dr. Weitzner’s and the putative class claims are covered under the Company’s general liability insurance policies. That matter is in its preliminary stages.

In January 2006, Gentle Laser Solutions, Inc., Liberty Bell Med Spa, Inc. and Kevin T. Campbell filed suit against Cynosure and one of its former directors, along with Sona International Inc. Sona Lasers Centers, Inc. and various other individuals, in the Superior Court of New Jersey. The matter was later removed to the United States District Court in the District of New Jersey. The suit alleged franchise act violations, fraud, breach of contract and other causes of action in connection with the plaintiffs’ acquisition of franchises from the Sona entities. The plaintiffs and Sona have settled the plaintiffs’ claims against Sona. On June 20, 2008, the court granted in part and denied in part Cynosure’s motion to dismiss the plaintiffs’ claims against Cynosure and its former director. The court dismissed, among other claims, the plaintiffs’ franchise act claims, as well as their claim for unjust enrichment. Cynosure has answered the remaining claims and filed an opposition to the plaintiffs’ motion for reconsideration of the court’s June 20, 2008 order on Cynosure’s motion to dismiss. The court has issued a scheduling order in the case and discovery has commenced. Cynosure is not able to estimate the amount or range of loss that could result from an unfavorable outcome of the lawsuit as the matter is still in the early stages of the proceedings.

On January 9, 2008, Cynosure commenced a lawsuit in the U.S. District Court for the District of Massachusetts against CoolTouch Inc. for infringement of U.S. Patent No. 6,206,873 (‘873 patent). Cynosure’s complaint alleges that CoolTouch’s “CoolLipo” infringes on the ‘873 patent and seeks damages and injunctive relief. On January 31, 2008, CoolTouch answered Cynosure’s complaint, denying liability and alleging that the ‘873 patent is not infringed and is invalid, and also asserted counterclaims against Cynsorure in the same court alleging patent infringement by Cynosure. CoolTouch’s counterclaim alleges that Cynosure’s Affirm product infringes U.S. Patent Nos. 7,122,029 and 6,451,007, and that Cynosure’s Smartlipo product infringes U.S. Patent No. 7,217,265, and seeks damages in an unspecified amount, as well as injunctive relief. Cynosure is vigorously prosecuting its claims against CoolTouch and defending against CoolTouch’s counterclaims. Cynosure is not able to estimate the amount or range of loss that could result from an unfavorable outcome of the lawsuit as the matter is still in the early stages of the proceedings.

In addition to the matters discussed above, from time to time, Cynosure is subject to various claims, lawsuits, disputes with third parties, investigations and pending actions involving various allegations against Cynosure incident to the operation of its business, principally product liability. Each of these other matters is subject to various uncertainties, and it is possible that some of these other matters may be resolved unfavorably to Cynosure. Cynosure establishes accruals for losses that management deems to be probable and subject to reasonable estimate. Cynosure believes that the ultimate outcome of these matters will not have a material adverse impact on its consolidated financial position, results of operations or cash flows.

Note 11 — Related Party Transactions

As of June 30, 2008, El. En. S.p.A. (El.En.) owned 23% of Cynosure’s outstanding common stock. Purchases of inventory from El.En. during the three months ended June 30, 2008 and 2007 were approximately $3.3 million and $2.2 million, respectively. Purchases of inventory from El.En. during the six months ended June 30, 2008 and 2007 were approximately $6.5 million and $3.7 million, respectively. As of June 30, 2008 and December 31, 2007, amounts due to related party for these purchases were approximately $3.2 million and $2.3 million, respectively. Amounts due from El.En. as of June 30, 2008 and December 31, 2007 were $20,000 and $8,000, respectively, which represent services performed by Cynosure.

Note 12 — Income Taxes

Effective January 1, 2007, Cynosure adopted the provisions of FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes, an Interpretation of FAS 109, Accounting for Income Taxes (FIN 48). At June 30, 2008, there are no material gross unrecognized tax benefits.

Cynosure files income tax returns in the U.S. federal jurisdiction, and in various state and foreign jurisdictions. With few exceptions, Cynosure is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2003.

Note 13 — Recent Accounting Pronouncements

In December 2007, the FASB issued Statement No. 141(R), Applying the Acquisition Method (SFAS 141(R)), which replaces FASB Statement No. 141, Business Combinations . SFAS 141(R) retains the fundamental requirements in Statement 141 that the acquisition method of accounting (which Statement 141 called the purchase method) be used for all business combinations and for an acquirer to be identified for each business combination. SFAS 141(R) defines the acquirer as the entity that obtains control of one or more businesses in the business combination and establishes the acquisition date as the date that the acquirer achieves control. Statement 141 did not define the acquirer, although it included guidance on identifying the acquirer, as does SFAS 141(R). SFAS 141(R)’s scope is broader than that of Statement 141, which applied only to business combinations in which control was obtained by transferring consideration. By applying the same method of accounting—the acquisition method—to all transactions and other events in which one entity obtains control over one or more other businesses, SFAS 141(R) improves the comparability of the information about business combinations provided in financial reports. SFAS 141(R) applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. Cynosure does not expect that the adoption of SFAS 141(R) will have a material impact on its financial position or results of operations upon adoption.

In December 2007, the FASB issued Statement No. 160, Noncontrolling Interests in Consolidated Financial Statements—an amendment of ARB No. 51 (SFAS 160), which applies to all entities that prepare consolidated financial statements, except not-for-profit organizations, but will affect only those entities that have an outstanding noncontrolling interest in one or more subsidiaries or that deconsolidate a subsidiary. SFAS 160 amends ARB 51 to establish accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. It clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements. SFAS 160 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. Earlier adoption is prohibited. SFAS 160 is required to be applied prospectively as of the beginning of the fiscal year in which it is initially applied, except for the presentation and disclosure requirements, which are required to be applied retrospectively for all periods presented. Cynosure does not expect that the adoption of SFAS 160 will have a material impact on its financial position or results of operations.

In February 2007, the FASB issued Statement No. 159, The Fair Value Option for Financial Assets and Financial Liabilities—Including an Amendment of FASB Statement No. 115 (SFAS 159) . SFAS 159 permits entities to choose to measure many financial instruments and certain other items at fair value. Cynosure adopted SFAS 159 on January 1, 2008 and elected not to measure any additional financial instruments or other items at fair value. Adoption of SFAS 159 did not have a material impact on Cynosure’s financial position or results of operations.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-looking statements

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this Quarterly Report regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about:

•

our ability to identify and penetrate new markets for our products and technology;

•

our ability to innovate, develop and commercialize new products;

•

our ability to obtain and maintain regulatory clearances;

•

our sales and marketing capabilities and strategy in the United States and internationally;

•

our intellectual property portfolio; and

•

our estimates regarding expenses, future revenues, capital requirements and needs for additional financing.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in our Annual Report on Form 10-K for the year ended December 31, 2007, particularly in Part I — Item 1A and in our other public filings with the Securities and Exchange Commission that could cause actual results or events to differ materially from the forward-looking statements that we make.

You should read this Quarterly Report and the documents that we have filed as exhibits to the Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect. It is routine for internal projections and expectations to change as the year or each quarter in the year progresses, and therefore it should be clearly understood that the internal projections and beliefs upon which we base our expectations are made as of the date of this Quarterly Report on Form 10-Q and may change prior to the end of each quarter or the year. While we may elect to update forward-looking statements at some point in the future, we do not undertake any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise.

The following discussion should be read in conjunction with, and is qualified in its entirety by, the condensed consolidated financial statements and notes thereto included in Item 1 of this Quarterly Report and the condensed consolidated financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Form 10-K filed with the SEC on March 13, 2008. Historical results and percentage relationships among any amounts in the financial statements are not necessarily indicative of trends in operating results for any future periods.

Company Overview

We develop and market aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular lesions and pigmented lesions, temporarily reduce the appearance of cellulite, treat wrinkles, skin texture, skin discoloration and skin tightening, and to perform minimally invasive procedures for LaserBodySculpting for the removal of unwanted fat. Our systems incorporate a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:Yag and diode lasers, as well as intense pulsed light. We believe that we are one of only a few companies that currently offer aesthetic treatment systems utilizing Alexandrite and pulse dye lasers, which are particularly well suited for some applications and skin types. We offer single energy source systems as well as workstations that incorporate two or more different types of lasers or pulsed light technologies. We offer multiple technologies and system alternatives at a variety of price points depending primarily on the number and type of energy sources included in the system. Our current products are designed to be easily upgradeable to add additional energy sources and handpieces, which provides our customers with technological flexibility as they expand their practices. As the aesthetic treatment market evolves to include new customers, such as aesthetic spas and additional physician specialties, we believe that our broad technology base and tailored solutions will provide us with a competitive advantage.

We sell 17 different aesthetic treatment systems and have focused our development and marketing efforts on offering leading, or flagship, products for each of the major aesthetic procedure categories that we address. Our flagship products are:

•

the Apogee Elite system for hair removal;

•

the Cynergy system for the treatment of vascular lesions;

•

the TriActive LaserDermology system for the temporary reduction of the appearance of cellulite;

•

the Affirm system for anti-aging, including treatments for wrinkles, skin texture, skin discoloration and skin tightening; and

•

the Smartlipo and Smartlipo MPX systems for LaserBodySculpting ^SM for the removal of unwanted fat; and

•

the Accolade system, which we introduced in January 2008, for the removal of benign pigmented lesions, including pigmented lesions known as Nevus of Ota and Nevus of Ito, as well as multi-colored tattoos.

During the three months ended June 30, 2008, we introduced and began shipping our Smartlipo MPX workstation, the next generation of our workstations for laser lipolysis. Smartlipo MPX is the only FDA-approved, dual-wavelength laser system designed to efficiently liquefy fat and tighten skin through collagen remodeling.

We generate revenues primarily from sales of our products and parts and accessories and, to a lesser extent, from services, including product warranty revenues. During the six months ended June 30, 2008 and 2007, we derived approximately 96% of our revenues from sales of our products and 4% of our revenues from service. Generally, we recognize revenues from the sales of our products upon delivery to our customers, revenues from service contracts and extended product warranties ratably over the coverage period and revenues from service in the period in which the service occurs.

We sell our products directly in North America, four European countries, Japan and China and use distributors to sell our products in other countries where we do not have a direct presence. During the six months ended June 30, 2008, we derived 32% and during the same period in 2007, we derived 40% of our revenues from sales outside North America. As of June 30, 2008, we had 77 sales employees in North America, 35 sales employees in four European countries, Japan and China and distributors in 53 countries.

The following table provides revenue data by geographical region for the six months ended June 30, 2008 and 2007:


	Percentage of Revenues
	Six-Months Ended June 30,
Region	2008		2007
North America	68	%	60	%
Europe	19		25
Asia/Pacific	10		11
Other	3		4

Total	100	%	100	%

See Note 7 to our consolidated financial statements included in this Quarterly Report for revenues and asset data by geographic region.

Results of Operations

THREE MONTHS ENDED JUNE 30, 2008 AND 2007

The following table contains selected income statement information, which serves as the basis of the discussion of our results of operations for the three months ended June 30, 2008 and 2007, respectively (in thousands, except for percentages):


	Three Months Ended June 30,
	2008					2007
	Amount			As a % of Total Revenues		Amount		As a % of Total Revenues		$ Change			% Change
Revenues	$	39,195		100	%	$	30,132	100	%	$	9,063		30	%
Cost of revenues		12,878		33			11,068	37			1,810		16

Gross profit		26,317		67			19,064	63			7,253		38
Operating expenses
Sales and marketing		14,085		36			9,875	33			4,210		43
Research and development		1,801		5			1,767	6			34		2
General and administrative		3,638		9			2,933	10			705		24

Total operating expenses		19,524		50			14,575	48			4,949		34

Income from operations		6,793		17			4,489	15			2,304		51
Interest income, net		627		2			596	2			31		5
Other (expense) income, net		(120	)	—			28	—			(148	)	(529	)

Income before provision for income taxes		7,300		19			5,113	17			2,187		43
Provision for income taxes		2,640		7			2,402	8			238		10

Net income	$	4,660		12	%	$	2,711	8	%	$	1,949		72	%

Revenues

Revenues in the three months ended June 30, 2008 exceeded revenues in the three months ended June 30, 2007 by $9.1 million or 30%. The increase in revenues was attributable to a number of factors (in thousands, except for percentages):


	Three Months Ended June 30,				$ Change		% Change
	2008		2007		$ Change		% Change
Product sales in North America	$	24,457	$	16,775	$	7,682	46	%
Product sales outside North America		10,646		9,851		795	8
Original equipment manufacturer sales and revenue sharing		330		277		53	19
Parts, accessories and service sales		3,762		3,230		532	16

Total Revenues	$	39,195	$	30,132	$	9,063	30	%

•

Revenues from the sale of products in North America increased by approximately $7.7 million, or 46%, over the 2007 period, due to an increase in the number of product units sold, a higher average selling price across all of our flagship products as well as a favorable change in product mix from new products introduced in the past year.

•

Revenues from sales of products outside of North America increased by approximately $0.8 million, or 8%, over the 2007 period, due to an increase in sales by our Asian and Middle Eastern distributors.

•

Revenues from the sale of parts, accessories and services increased by approximately $0.5 million, or 16%, over the 2007 period, primarily as a result of an increase in revenues generated from the sale of disposable components, related to our Affirm and Smartlipo systems that were introduced in the past year. The increase also related to an increase in revenues generated from service contracts and the sale of parts, over the 2007 period, both of which are related to the overall increase in volume of sales during the past three years.

Cost of Revenues


	Three Months Ended June 30,						$ Change		% Change
	2008			2007			$ Change		% Change
Cost of revenues (in thousands)	$	12,878		$	11,068		$	1,810	16	%
Cost of revenues (as a percentage of total revenues)		33	%		37	%

The increase in the cost of revenues was primarily attributable to an increase in direct labor, overhead and material costs associated with increased sales of our products. Our cost of revenues decreased as a percentage of revenues to 33% for the three months ended June 30, 2008, from 37% for the three months ended June 30, 2007, resulting in an increase in our gross margin of 4%, quarter over quarter. The improvement in gross margins is primarily the result of higher average selling prices of our products, a favorable change in product mix and increased contribution from direct sales.

Sales and Marketing


	Three Months Ended June 30,						$ Change		% Change
	2008			2007			$ Change		% Change
Sales and marketing (in thousands)	$	14,085		$	9,875		$	4,210	43	%
Sales and marketing (as a percentage of total revenues)		36	%		33	%

Sales and marketing expenses increased primarily due to an increase of $1.3 million in personnel costs and travel expenses associated with the expansion of our North American direct sales organization, which includes an increase of $0.5 million in commission expense. Personnel costs and travel expenses associated with our international subsidiaries increased by $0.5 million, due to the expansion of our worldwide sales and marketing force, particularly at the management level. Promotional costs increased $1.6 million, primarily due to an increased number of clinical workshops, trade shows and other promotional efforts, as well as increased spending on international related marketing efforts. Sales and marketing expenses also increased due to an increase in stock-based compensation of approximately $0.4 million and a $0.4 million increase in clinical development and education related expenses.

Research and Development


	Three Months Ended June 30,						$ Change		% Change
	2008			2007			$ Change		% Change
Research and development (in thousands)	$	1,801		$	1,767		$	34	2	%
Research and development (as a percentage of total revenues)		5	%		6	%

Research and development expenses remained relatively consistent period over period and we expect these expenses as a percentage of total revenues to remain relatively consistent for the foreseeable future.

General and Administrative


	Three Months Ended June 30,						$ Change		% Change
	2008			2007			$ Change		% Change
General and administrative (in thousands)	$	3,638		$	2,933		$	705	24	%
General and administrative (as a percentage of total revenues)		9	%		10	%

General and administrative expenses increased primarily due to an increase in personnel costs of $0.2 million and an increase in stock-based compensation of $0.1 million. General and administrative expenses also increased due to an increase in legal and professional service related costs of $0.2 million and an increase in bad debt expense of approximately $0.2 million associated with our international subsidiaries

Interest Income, net and Other Income, net


	Three Months Ended June 30,					$ Change			% Change
	2008			2007		$ Change			% Change
Interest income, net (in thousands)	$	627		$	596	$	31		5	%
Other (expense) income, net (in thousands)	$	(120	)	$	28	$	(148	)	(529	)%

The increase in interest income, net resulted from an overall $16.4 million, or 28%, increase in our total investment portfolio from $58.8 million as of June 30, 2007 to $75.2 million as of June 30, 2008, offset by a decrease in interest rates, period over period. The variance in other (expense) income, net is a result of foreign currency remeasurement losses generated in the second quarter of 2008 compared to the foreign currency remeasurement gains generated the second quarter of 2007.

Provision for Income Taxes


	Three Months Ended June 30,						$ Change		% Change
	2008			2007			$ Change		% Change
Provision for income taxes (in thousands)	$	2,640		$	2,402		$	238	10	%
Provision as a % of income before provision for income taxes		36	%		47	%

The increase in our provision for income taxes is primarily attributable to the $2.2 million increase in our income before provision for income taxes from $5.1 million in 2007 to $7.3 million in 2008. The increase in the provision for income taxes is partially offset by a reduction in our tax rate, as well as a provision for income taxes recorded during the three months ended June 30, 2007 related to a prior period examination by the Internal Revenue Service, which contributed to the decrease in our provision as a percentage of income before provision for income taxes.

SIX MONTHS ENDED JUNE 30, 2008 AND 2007

The following table contains selected income statement information, which serves as the basis of the discussion of our results of operations for the six months ended June 30, 2008 and 2007, respectively (in thousands, except for percentages):


	Six Months Ended June 30,
	2008				2007
			As a % of				As a % of
	Amount		Total Revenues		Amount		Total Revenues		$ Change		% Change
Revenues	$	75,958	100	%	$	56,209	100	%	$	19,749	35	%
Cost of revenues		25,249	33			20,990	37			4,259	20

Gross profit		50,709	67			35,219	63			15,490	44
Operating expenses
Sales and marketing		27,279	36			19,137	34			8,142	43
Research and development		3,614	5			3,490	6			124	4
General and administrative		7,125	9			5,228	9			1,897	36

Total operating expenses		38,018	50			27,855	49			10,163	36

Income from operations		12,691	17			7,364	13			5,327	72
Interest income, net		1,428	2			1,101	2			327	30
Other income, net		434	—			84	—			350	417

Income before provision for income taxes		14,553	19			8,549	16			6,004	70
Provision for income taxes		5,024	7			3,720	7			1,304	35

Net income	$	9,529	13	%	$	4,829	9	%	$	4,700	97	%

Revenues

Revenues in the six months ended June 30, 2008 exceeded revenues in the six months ended June 30, 2007 by $19.7 million or 35%. The increase in revenues was attributable to a number of factors (in thousands, except for percentages):


	Six Months Ended June 30,				$ Change		% Change
	2008		2007		$ Change		% Change
Product sales in North America	$	48,068	$	30,954	$	17,114	55	%
Product sales outside North America		19,871		18,621		1,250	7
Original equipment manufacturer sales and revenue sharing		703		551		152	28
Parts, accessories and service sales		7,316		6,083		1,233	20

Total Revenues	$	75,958	$	56,209	$	19,749	35	%

•

Revenues from the sale of products in North America increased by approximately $17.1 million, or 55%, over the 2007 period, due to an increase in the number of product units sold, a higher average selling price across all of our flagship products as well as a favorable change in product mix from new products introduced in the past year.

•

Revenues from sales of products outside of North America increased by approximately $1.3 million, or 7%, over the 2007 period, due to an increase in sales by our Asian distributors.

•

Revenues from original equipment manufacturer sales and revenue sharing increased by approximately $0.2 million, or 28%, over the 2007 period, due to an increase in revenue sharing revenues generated by our European subsidiaries.

•

Revenues from the sale of parts, accessories and services increased by approximately $1.2 million, or 20%, over the 2007 period, primarily as a result of an increase in revenues generated from the sale of disposable components, related to our Affirm and Smartlipo systems that were introduced in the past year. The increase also related to an increase in revenues generated from service contracts and the sale of parts, over the 2007 period, both of which are related to the overall increase in volume of sales during the past three years.

Cost of Revenues


	Six Months Ended June 30,						$ Change		% Change
	2008			2007			$ Change		% Change
Cost of revenues (in thousands)	$	25,249		$	20,990		$	4,259	20	%
Cost of revenues (as a percentage of total revenues)		33	%		37	%

The increase in the cost of revenues was primarily attributable to an increase in direct labor, overhead and material costs associated with increased sales of our products. Our cost of revenues decreased as a percentage of revenues to 33% for the six months ended June 30, 2008, from 37% for the six months ended June 30, 2007, resulting in an increase in our gross margin of 4%, quarter over quarter. The improvement in gross margins is primarily the result of higher average selling prices of our products, a favorable change in product mix and increased contribution from direct sales.

Sales and Marketing


	Six Months Ended June 30,						$ Change		% Change
	2008			2007			$ Change		% Change
Sales and marketing (in thousands)	$	27,279		$	19,137		$	8,142	43	%
Sales and marketing (as a percentage of total revenues)		36	%		34	%

Sales and marketing expenses increased primarily due to an increase of $3.3 million in personnel costs and travel expenses associated with the expansion of our North American direct sales organization, which includes an increase of $1.5 million in commission expense. Personnel costs and travel expenses associated with our international subsidiaries increased by $0.7 million, due to the expansion of our worldwide sales and marketing force, particularly at the management level. Promotional costs increased $3.1 million, primarily due to an increased number of clinical workshops, trade shows and other promotional efforts, as well as increased spending on international related marketing efforts. Sales and marketing expenses also increased due to an increase in stock-based compensation of approximately $0.7 million and a $0.6 million increase in clinical marketing and development related expenses.

Research and Development


	Six Months Ended June 30,						$ Change		% Change
	2008			2007			$ Change		% Change
Research and development (in thousands)	$	3,614		$	3,490		$	124	4	%
Research and development (as a percentage of total revenues)		5	%		6	%

General and Administrative


	Six Months Ended June 30,						$ Change		% Change
	2008			2007			$ Change		% Change
General and administrative (in thousands)	$	7,125		$	5,228		$	1,897	36	%
General and administrative (as a percentage of total revenues)		9	%		9	%

General and administrative expenses increased due to an increase in legal and professional service related costs of $0.8 million, an increase in personnel costs of $0.6 million, as well as an increase in stock-based compensation of $0.3 million. General and administrative expenses also increased due to an increase in bad debt expense of approximately $0.2 million associated with our international subsidiaries.

Interest Income, net and Other Income, net


	Six Months Ended June 30,				$ Change		% Change
	2008		2007		$ Change		% Change
Interest income, net (in thousands)	$	1,428	$	1,101	$	327	30	%
Other income, net (in thousands)	$	434	$	84	$	350	417	%

The increase in interest income, net resulted from an overall $16.4 million, or 28%, increase in our total investment portfolio from $58.8 million as of June 30, 2007 to $75.2 million as of June 30, 2008, offset by a decrease in interest rates, period over period. The variance in other income, net is a result of greater foreign currency remeasurement gains in the first six months of 2008 compared to the foreign currency remeasurement gains in the first six months of 2007.

Provision for Income Taxes


	Six Months Ended June 30,						$ Change		% Change
	2008			2007			$ Change		% Change
Provision for income taxes (in thousands)	$	5,024		$	3,720		$	1,304	35	%
Provision as a % of income before provision for income taxes and minority interest		35	%		44	%

The increase in our provision for income taxes is primarily attributable to the $6.0 million increase in our income before provision for income taxes from $8.5 million in 2007 to $14.6 million in 2008. The increase in the provision for income taxes is partially offset by a reduction in our tax rate, as well as a provision for income taxes recorded during the six months ended June 30, 2007 related to a prior period examination by the Internal Revenue Service, which contributed to the decrease in our provision as a percentage of income before provision for income taxes.

Liquidity and Capital Resources

We require cash to pay our operating expenses, make capital expenditures and pay our long-term liabilities. Since our inception, we have funded our operations through private and public placements of equity securities, short-term borrowings and funds generated from our operations. At June 30, 2008, our cash, cash equivalents, marketable securities and long-term investments were $91.5 million. Our cash and cash equivalents of $50.5 million are highly liquid investments with maturity of 90 days or less at date of purchase and consist of time deposits and investments in money market funds with commercial banks and financial institutions. Our marketable securities of $19.5 million consist primarily of investments in various state and municipal government and corporate obligations, all of which mature by January 19, 2010. Included in our marketable securities are investments in auction rate securities of approximately $2.95 million, which were called at full par value and settled in July 2008. Our long-term investments of $21.5 million consist primarily of tax exempt certificates with an auction reset feature (auction rate securities), whose underlying assets are generally student loans, which are substantially backed by the federal government.

In February 2008, auctions began to fail for auction rate securities and each auction since then has failed. Based on the overall failure rate of these auctions, the frequency of the failures, and the underlying maturities of the securities, a portion of which are greater than 30 years, we have classified auction rate securities as long-term assets on our consolidated balance sheet. These investments were valued at fair value as of June 30, 2008. See Note 4 to our consolidated financial statements.

All of our auction rate securities have at least an AA credit rating with the majority at an AAA credit rating. If the issuers are unable to successfully close future auctions or refinance their debt in the near term and their credit ratings deteriorate, we may, in the future, be required to record an impairment charge on these investments. Based on our expected operating cash flows and our other sources of cash, we do not anticipate the current lack of liquidity on these investments will affect our ability to execute our current business plan.

We expect to continue to generate positive cash flows from operations in the future. Our future capital requirements depend on a number of factors, including the rate of market acceptance of our current and future products, the resources we devote to developing and supporting our products and continued progress of our research and development of new products. Due to certain significant capital expenditures incurred during the six months ended June 30, 2008, including the expansion of our corporate headquarters facility and the implementation of a new financial software system, we expect that capital expenditures during the next 12 months will be consistent with our capital expenditures during the 12 months ended December 31, 2007.

We believe that our current cash, cash equivalents and marketable securities, as well as cash generated from operations, will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for the foreseeable future.

Cash Flows

Net cash provided by operating activities was $9.7 million for the six months ended June 30, 2008. This resulted primarily from net income for the period of $9.5 million, increased by approximately $5.4 million in depreciation and amortization and stock-based compensation expense and increased by approximately $0.2 million in accretion of discounts on marketable securities. Net changes in working capital items decreased cash from operating activities by approximately $5.4 million principally related to an increase in accounts receivable due to an increase in sales, particularly in the last month of the quarter as the result of our introduction of the Smartlipo MPX systems, and an increase in inventory for anticipated future sales, offset by an increase in accounts payable and deferred revenue. Net cash provided by investing activities was $1.0 million for the six months ended June 30, 2008, which consisted primarily of the net proceeds of $4.6 million from the sales and maturities of marketable securities, offset by purchases of marketable securities, and offset by $3.6 million used for fixed asset purchases. Net cash provided by financing activities during the six months ended June 30, 2008 was $1.4 million, principally relating to proceeds from stock option exercises and related tax benefits.

Net cash provided by operating activities was $10.4 million for the six months ended June 30, 2007. This resulted primarily from net income for the period of $4.8 million, increased by approximately $4.2 million in depreciation and stock-based compensation expense and increased by approximately $0.1 million in deferred income tax benefits and accretion of discounts on marketable securities. Net changes in working capital items increased cash from operating activities by approximately $1.3 million principally related to a increase in accrued expenses and deferred revenue of $3.4 million and $1.7 million, respectively, a decrease in prepaid expenses and other current assets of $1.6 million and an increase in amounts due to related party of $1.3 million, offset by an increase in inventory for anticipated future sales and an increase in accounts receivable. Net cash used in investing activities was $6.9 million for the six months ended June 30, 2007, which consisted primarily of the net purchase of $4.9 million of marketable securities and $2.0 million used for fixed asset purchases. Net cash provided by financing activities during the six months ended June 30, 2007 was $6.1 million, principally relating to proceeds from option exercises and tax benefits related to stock options.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations set forth above are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate our estimates and judgments, including those that relate to revenue recognition, allowances for doubtful accounts, inventories, warranty obligations, stock-based compensation and income taxes. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities, and the reported amounts of revenues and expenses, that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. A discussion of our critical accounting policies and the related judgments and estimates affecting the preparation of our consolidated financial statements is included in the Annual Report on our Form 10-K fiscal year 2007. There have been no material changes to our critical accounting policies as of June 30, 2008.

Recent Accounting Pronouncements

In December 2007, the FASB issued Statement No. 141(R), Applying the Acquisition Method (SFAS 141(R)), which replaces FASB Statement No. 141, Business Combinations . SFAS 141(R) retains the fundamental requirements in Statement 141 that the acquisition method of accounting (which Statement 141 called the purchase method) be used for all business combinations and for an acquirer to be identified for each business combination. SFAS 141(R) defines the acquirer as the entity that obtains control of one or more businesses in the business combination and establishes the acquisition date as the date that the acquirer achieves control. Statement 141 did not define the acquirer, although it included guidance on identifying the acquirer, as does SFAS 141(R). SFAS 141(R)’s scope is broader than that of Statement 141, which applied only to business combinations in which control was obtained by transferring consideration. By applying the same method of accounting—the acquisition method—to all transactions and other events in which one entity obtains control over one or more other businesses, SFAS 141(R) improves the comparability of the information about business combinations provided in financial reports. SFAS 141(R) applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. We do not expect that the adoption of SFAS 141(R) will have a material impact on our financial position or results of operations.

In December 2007, the FASB issued Statement No. 160, Noncontrolling Interests in Consolidated Financial Statements—an amendment of ARB No. 51 (SFAS 160), which applies to all entities that prepare consolidated financial statements, except not-for-profit organizations, but will affect only those entities that have an outstanding noncontrolling interest in one or more subsidiaries or that deconsolidate a subsidiary. SFAS 160 amends ARB 51 to establish accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. It clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements. SFAS 160 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. Earlier adoption is prohibited. SFAS 160 is required to be applied prospectively as of the beginning of the fiscal year in which it is initially applied, except for the presentation and disclosure requirements, which are required to be applied retrospectively for all periods presented. We do not expect that the adoption of SFAS 160 will have a material impact on our financial position or results of operations.

In February 2007, the FASB issued Statement No. 159, The Fair Value Option for Financial Assets and Financial Liabilities—Including an Amendment of FASB Statement No. 115 (SFAS 159) . SFAS 159 permits entities to choose to measure many financial instruments and certain other items at fair value. We adopted SFAS 159 on January 1, 2008 and elected not to measure any additional financial instruments or other items at fair value. Adoption of SFAS 159 did not have a material impact on our financial position or results of operations.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

The following discussion about our market risk disclosures involves forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. We are exposed to market risk related to changes in interest rates and foreign currency exchange rates. We do not use derivative financial instruments.

Interest Rate Sensitivity. We maintain an investment portfolio consisting mainly of state and municipal government obligations, some of which are auction rate securities, corporate obligations and money market funds. The securities, other than money market funds, are classified as available-for-sale and consequently are recorded on the balance sheet at fair value with unrealized gains and losses reported as a separate component of accumulated other comprehensive income (loss). All investments other than auction rate securities mature by January 19, 2010. These available-for-sale securities are subject to interest rate risk and will fall in value if market interest rates increase, which could result in a realized loss if we are forced to sell an investment before its scheduled maturity. We currently have the ability and intent to hold our fixed income investments until maturity (excluding acquisitions or mergers). We do not utilize derivative financial instruments to manage our interest rate risks.

The following table provides information about our investment portfolio in available-for-sale debt securities. For investment securities, the table presents principal cash flows (in thousands) and weighted average interest rates by expected maturity dates.


	June 30, 2008			FY 2008			FY 2009			FY 2010			Thereafter
Investments (at fair value)	$	40,982		$	11,669		$	6,379		$	1,428		$	21,506
Weighted average interest rate		3.98	%		4.80	%		5.13	%		6.31	%		3.04	%

As of June 30, 2008, we held approximately $24.5 million of auction rate securities, $21.5 million of which is classified as long-term assets and $2.95 million is classified as marketable securities in current assets since the securities were called on July 1, 2008. On July 9, 2008, an additional $1.2 million, related to another investment in auction rate securities, was successfully called at full par value. As of June 30, 2008, this investment was included in long-term assets and valued accordingly, as the announcement of the settlement was not made until July. The underlying assets of these auction rate securities are generally student loans, which are substantially backed by the federal government. In February 2008, auctions began to fail for these securities and each auction since then has failed. Effective January 1, 2008, we determine the fair market values of our financial instruments based on the fair value hierarchy established in SFAS 157, which requires an entity to maximize the use of observable inputs (Level 1 and Level 2 inputs) and minimize the use of unobservable inputs (Level 3 inputs) when measuring fair value. Given the current failures in the auction markets to provide quoted market prices of the securities as well as the lack of any correlation of these instruments to other observable market data, we valued these securities using a discounted cash flow methodology with the most significant input categorized as Level 3. Significant inputs that went into the model were the credit quality of the issuer, the percentage and types of guarantees (such as Federal Family Education Loan Program – FFELP), the probability of the auction succeeding or the security being called, the estimated period to liquidation, and an illiquidity discount factor. Based on these inputs, discounts from par ranged from 3% to 12% with a weighted average discount across the portfolio of 4%. Changes in the assumptions of our model based on dynamic market conditions could have a significant impact on the valuation of these securities, which may lead us in the future to record an impairment charge for these securities.

Foreign Currency Exchange. A significant portion of our operations is conducted through operations in countries other than the United States. Revenues from our international operations that were recorded in U.S. dollars represented approximately 45% of our total international revenues during the six months ended June 30, 2008. Substantially all of the remaining 55% were sales in euros, British pounds, Japanese yen and Chinese yuan. Since we conduct our business in U.S. dollars, our main exposure, if any, results from changes in the exchange rate between these currencies and the U.S. dollar. Our functional currency is the U.S. dollar. Our policy is to reduce exposure to exchange rate fluctuations by having most of our assets and liabilities, as well as most of our revenues and expenditures, in U.S. dollars, or U.S. dollar linked. Therefore, we believe that the potential loss that would result from an increase or decrease in the exchange rate is immaterial to our business and net assets.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2008. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2008, our principal executive officer and principal financial officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended June 30, 2008 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — Other Information

Item 1.

Legal Proceedings

In May 2005, Dr. Ari Weitzner, individually and as putative representative of a purported class, filed a complaint against us under the federal Telephone Consumer Protection Act (TCPA) in Massachusetts Superior Court in Middlesex County seeking monetary damages, injunctive relief, costs and attorneys fees. The complaint alleges that we violated the TCPA by sending unsolicited advertisements by facsimile to the plaintiff and other recipients without the prior express invitation or permission of the recipients. Under the TCPA, recipients of unsolicited facsimile advertisements are entitled to damages of up to $500 per facsimile for inadvertent violations and up to $1,500 per facsimile for knowing or willful violations. Based on discovery in this matter, the plaintiff alleges that approximately three million facsimiles were sent on our behalf by a third party to approximately 100,000 individuals. On February 6, 2008, several months after the close of discovery, the plaintiff served a motion for class certification, which we vigorously opposed on numerous factual and legal grounds, including that a nationwide class action may not be maintained in a Massachusetts state court by Dr. Weitzner, a New York resident; individual issues predominate over common issues; a class action is not superior to other methods of resolving TCPA claims; and Dr. Weitzner is an inadequate class representative. We also believe we have many merits defenses, including that the faxes in question do not constitute “advertising” within the meaning of the TCPA and many recipients had an established business relationship with us and are thereby deemed to have consented to the receipt of facsimile communications. The court held a hearing on the plaintiff’s class certification motion on June 17, 2008. On July 16, 2008, we commenced a declaratory judgment action in the United States District Court for the District of Massachusetts requesting a declaration that Dr. Weitzner’s and the putative class claims are covered under our general liability insurance policies. That matter is in its preliminary stages.

In January 2006, Gentle Laser Solutions, Inc., Liberty Bell Med Spa, Inc. and Kevin T. Campbell filed suit against us and one of our former directors, along with Sona International Inc. Sona Lasers Centers, Inc. and various other individuals, in the Superior Court of New Jersey. The matter was later removed to the United States District Court in the District of New Jersey. The suit alleged franchise act violations, fraud, breach of contract and other causes of action in connection with the plaintiffs’ acquisition of franchises from the Sona entities. The plaintiffs and Sona have settled all claims against Sona. On June 20, 2008, the court granted in part and denied in part our motion to dismiss the plaintiffs’ claims against us and our former director. The court dismissed, among other claims, the plaintiffs’ franchise act claims, as well as their claim for unjust enrichment. We have answered the remaining claims and filed an opposition to the plaintiffs’ motion for reconsideration of the court’s June 20, 2008 order on our motion to dismiss. The court has issued a scheduling order in the case and discovery has commenced. We have moved to dismiss the plaintiffs’ claims against us. We are not able to estimate the amount or range of loss that could result from an unfavorable outcome of the lawsuit as the matter is still in the early stages of the proceedings.

On January 9, 2008, we commenced a lawsuit in the U.S. District Court for the District of Massachusetts against CoolTouch Inc. for infringement of U.S. Patent No. 6,206,873 (‘873 patent). Our complaint alleges that CoolTouch’s “CoolLipo” infringes on the ‘873 patent and seeks damages and injunctive relief. On January 31, 2008, CoolTouch answered our complaint, denying liability and alleging that the ‘873 patent is not infringed and is invalid, and also asserted counterclaims against us in the same court alleging patent infringement. CoolTouch’s counterclaim alleges that our Affirm product infringes U.S. Patent Nos. 7,122,029 and 6,451,007, and that our Smartlipo product infringes U.S. Patent No. 7,217,265, and seeks damages in an unspecified amount, as well as injunctive relief. We are vigorously prosecuting our claims against CoolTouch and defending against CoolTouch’s counterclaims. We are not able to estimate the amount or range of loss that could result from an unfavorable outcome of the lawsuit as the matter is still in the early stages of the proceedings.

In addition to the matters discussed above, from time to time, we are subject to various claims, lawsuits, disputes with third parties, investigations and pending actions involving various allegations against us incident to the operation of our business, principally product liability. Each of these other matters is subject to various uncertainties, and it is possible that some of these other matters may be resolved unfavorably to us. We establish accruals for losses that management deems to be probable and subject to reasonable estimate. We believe that the ultimate outcome of these matters will not have a material adverse impact on its consolidated financial position, results of operations or cash flows.

Item 1A.

Risk Factors

Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2007 in addition to the other information included in this quarterly report. If any of the risks actually occurs, our business, financial condition or results of operations would likely suffer. In that case, the trading price of our common stock could fall.

As of June 30, 2008, there have been no material changes to the risk factors disclosed in our annual report on Form 10-K for the fiscal year ended December 31, 2007, although we may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

On December 13, 2005, we completed an initial public offering (IPO) of 5,750,000 shares of our class A common stock at a price to the public of $15.00 per share. We sold 4,750,000 shares of the class A common stock, including an over-allotment option of 750,000 shares, and El.En., the selling shareholder in the offering, sold 1,000,000 of the shares. The offer and sale of all of the shares in the initial public offering were registered under the Securities Act of 1933, as amended, pursuant to a registration statement on Form S-1 (File No. 333-127463), which was declared effective by the SEC on November 8, 2005. We received aggregate net proceeds of approximately $64.0 million, after deducting underwriting discounts and commission of approximately $5.0 million and expenses of the offering of approximately $2.3 million. None of the underwriting discounts and commissions or offering expenses were incurred or paid to directors or officers of ours or their associates or to persons owning 10 percent or more of our common stock or to any affiliates of ours.

From the effective date of the registration statement through December 31, 2005, we used approximately $2.6 million for general corporate purposes. From the effective date of the registration statement through December 31, 2006, we used approximately $49.6 million for general corporate purposes. From the effective date of the registration statement through June 30, 2007, we used approximately $64.0 million for general corporate purposes, and as of June 30, 2007, all proceeds from our IPO had been utilized.

Our total cash, cash equivalents, marketable securities and long-term investments balance was $91.5 million as of June 30, 2008.

We did not sell any unregistered securities during the period covered by this Quarterly Report on Form 10-Q.

Item 4.

Submission of Matters to a Vote of Security Holders

We held our 2008 Annual Meeting of Stockholders on May 14, 2008. At the 2008 Annual Meeting, our stockholders elected all of the director nominees and ratified the selection of Ernst & Young LLP as our independent registered public accounting firm for 2008.

Holders of our class A and class B common stock, voting together as a single class, elected Michael R. Davin to serve as our class III classified director until our 2011 annual meeting of stockholders and until his successor is elected and qualified. Holders of our class B common stock, voting as a separate class, elected Ettore V. Biagioni, Andrea Cangioli, Leonardo Masotti and George J. Vojta to serve as our class B directors until our 2008 annual meeting and until their successors are elected and qualified. In addition to the directors listed above who were elected at the 2008 Annual Meeting, the terms as directors of Paul F. Kelleher and Thomas H. Robinson continued after the 2008 Annual Meeting.

The matters acted upon at the 2008 Annual Meeting, and the voting tabulation for each matter, are as follows:


Proposal 1:		The election of one class III classified director for the next three years (voted on by holders of class A common stock and class B common stock, voting together as a single class):


Nominee	Votes For	Votes Withheld
Michael R. Davin	10,883,829	632,199


Proposal 2:		The election of four class B directors for the next year; (voted on by the holders of class B common stock, voting as a separate class):


Nominee	Votes For	Votes Withheld
Ettore V. Biagioni	2,938,628	0
Andrea Cangioli	2,938,628	0
Leonardo Masotti	2,938,628	0
George J. Vojta	2,938,628	0


Proposal 3:		Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2008 (voted on by holders of class A common stock and class B common stock, voting together as a single class):


Votes For	Votes Against	Abstain
11,434,567	76,781	4,679

Item 6.

Exhibits

(a)

Exhibits


Exhibit No.		Description
31.1		Certification of the Principal Executive Officer

31.2		Certification of the Principal Financial Officer

32.1		Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2		Certification of the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant certifies that it has caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.


	Cynosure, Inc.
	(Registrant)

Date: August 11, 2008	By:	/s/ Michael R. Davin
		Michael R. Davin
		Chairman, President, Chief Executive Officer

Date: August 11, 2008	By:	/s/ Timothy W. Baker
		Timothy W. Baker
		Executive Vice President, Chief Financial Officer and Treasurer

EXHIBIT INDEX


Exhibit No.		Description
31.1		Certification of the Principal Executive Officer

31.2		Certification of the Principal Financial Officer

32.1		Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2		Certification of the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002